FDA has cleared IND application of LT-010, a first-in-class small nucleic acid for AGA therapy, which developed from lacTAC Bio proprietary transdermal delivery platform.

The founding members firstly chose the English name "lncTAC" which is an acronym based on our technology platform "lncRNA-based Targeting Chimera."